Plitidepsin vs Kahalalide F
Head-to-head comparison of Plitidepsin (Dehydrodidemnin B (Plitidepsin)) and Kahalalide F (Kahalalide F) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plitidepsin | Kahalalide F |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Dehydrodidemnin B (Plitidepsin) | Kahalalide F |
| Molecular Weight | 1110.3 Da | 1111.3 Da |
| Half-Life | Approximately 44 hours | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | 1.5 mg/m2 IV | 0.1-3 mg/m2 IV in early trials |
| Route | Intravenous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 240 | 85 |
| Research Status | Clinical | Pre-clinical |
Plitidepsin Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓anti-inflammatory
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
Plitidepsin Dosing
1.5 mg/m2 IV infusion in oncology trials|q21d or similar intermittent schedules|dose escalation and combination protocols in studies
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
Plitidepsin Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠transaminase elevation
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Research Overview
Plitidepsin
Plitidepsin has been studied for its ability to disrupt eEF1A-dependent pathways, induce oxidative stress, and suppress tumor cell growth. It has reached clinical oncology development and was also evaluated as a candidate against SARS-CoV-2 in the literature.
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.